Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ASLAN Approved to Start Singapore-Taiwan Trial of Cancer Drug

publication date: Sep 15, 2015
ASLAN Pharma, a Singapore-based biotech focused on cancer, reports it has received approvals to conduct a clinical Phase II trial in Singapore and Taiwan of ASLAN001 (varlitinib) as a  second-line treatment for cholangiocarcinoma. Cholangiocarcinoma, the second most prevalent form of liver cancer, is an aggressive form of bile duct cancer with no approved therapy. In August, ASLAN001 was granted Orphan Drug status in the US for the disease. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital